Landmark study reveals EDE-like antibodies crucial for broad immunity against dengue
A novel study published in Science Translational Medicine has identified envelope dimer epitope (EDE)-like antibodies as key to developing broad, cross-serotype immunity against dengue. This finding is significant because initial dengue infection paradoxically increases the risk of severe disease upon secondary infection with a different serotype, a phenomenon called antibody-dependent enhancement. The study, conducted in the Philippines, found high prevalence of EDE-like antibodies in individuals with secondary immunity, strongly correlating with protection against symptomatic and severe dengue across multiple serotypes. This research offers a pathway to developing more effective dengue vaccines that specifically target the elicitation of EDE-like antibodies.
Key Points
- A new study identifies EDE-like antibodies as crucial for broad, cross-serotype immunity against dengue.
- Initial dengue infection can paradoxically increase the risk of severe disease upon subsequent infection with a different serotype due to antibody-dependent enhancement.
- EDE-like antibodies were found to be highly prevalent in individuals with secondary dengue immunity and correlated with protection against severe disease.
- This research offers a pathway to developing more effective dengue vaccines that specifically target the elicitation of EDE-like antibodies.
Exam Facts
- The study was published in Science Translational Medicine.
- It was conducted in Cebu province, Philippines.
- Dengue is caused by four DENV serotypes (DENV1 to DENV4).
- The phenomenon of increased severe disease risk upon secondary infection is called antibody-dependent enhancement.
- Existing dengue vaccines mentioned are Dengvaxia and QDENGA.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.